BOUNDLESS BIO, INC. Payments to Acquire Investments
BOUNDLESS BIO, INC. (BOLD) reported Payments to Acquire Investments of $37.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-07
- BOUNDLESS BIO, INC. payments to acquire investments for the quarter ending 2026-06-30 was $8.39M, a 80.77% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire investments for the quarter ending 2026-03-31 was $29.41M, a 44.12% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire investments for the quarter ending 2025-12-31 was $39.10M, a 17.56% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire investments for the quarter ending 2025-09-30 was $39.51M, a 8.60% increase year-over-year.
- BOUNDLESS BIO, INC. payments to acquire investments for fiscal 2025 was $174.90M, a 16.10% decline from fiscal 2024.
- BOUNDLESS BIO, INC. payments to acquire investments for fiscal 2024 was $208.47M, a 30.19% increase from fiscal 2023.
- BOUNDLESS BIO, INC. payments to acquire investments for fiscal 2023 was $160.12M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $37.80M 10-Q · filed 2026-08-07 | $76.91M derived: sum of 3 quarters · filed 2026-08-07 | $116.41M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $29.41M 10-Q · filed 2026-05-08 | $68.51M derived: sum of 2 quarters · filed 2026-05-08 | $108.02M derived: sum of 3 quarters · filed 2026-05-08 | $151.68M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $39.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $78.61M derived: sum of 2 quarters · filed 2026-03-09 | $122.27M derived: sum of 3 quarters · filed 2026-08-07 | $174.90M 10-K · filed 2026-03-09 |
| 2025-09-30 | $39.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $83.17M derived: sum of 2 quarters · filed 2026-08-07 | $135.79M 10-Q · filed 2025-11-05 | $183.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $43.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $96.28M 10-Q · filed 2026-08-07 | $143.72M derived: sum of 3 quarters · filed 2026-08-07 | $180.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $52.63M 10-Q · filed 2026-05-08 | $100.06M derived: sum of 2 quarters · filed 2026-05-08 | $136.44M derived: sum of 3 quarters · filed 2026-05-08 | $240.06M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $47.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $83.81M derived: sum of 2 quarters · filed 2026-03-09 | $187.44M derived: sum of 3 quarters · filed 2026-03-09 | $208.47M 10-K · filed 2026-03-09 |
| 2024-09-30 | $36.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $140.00M derived: sum of 2 quarters · filed 2025-11-05 | $161.03M 10-Q · filed 2025-11-05 | $188.45M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $103.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $124.65M 10-Q · filed 2025-08-05 | $152.07M derived: sum of 3 quarters · filed 2025-08-05 | $187.39M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $21.02M 10-Q · filed 2025-05-09 | $48.45M derived: sum of 2 quarters · filed 2025-05-09 | $83.76M derived: sum of 3 quarters · filed 2025-05-09 | $171.15M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $27.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $62.74M derived: sum of 2 quarters · filed 2025-03-27 | $150.13M derived: sum of 3 quarters · filed 2025-03-27 | $160.12M 10-K · filed 2025-03-27 |
| 2023-09-30 | $35.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $122.71M derived: sum of 2 quarters · filed 2024-11-07 | $132.70M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $87.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $97.39M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $9.99M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |